newsfilter
← Latest News
Business Wire·

VBI Vaccines Reports Second Quarter 2023 Financial Results

PreHevbrio (Hepatitis B Vaccine [Recombinant]) global net revenue increased 48% quarter-over-quarter from Q1 to Q2 2023 - redefined, highly targeted commercial field team deployed at the end of Q2 Expanded hepatitis